Interpretation updates of the 2025 NCCN Guidelines on diagnosis and treatment for prostate cancer

doi:10.3877/cma.j.issn.1674-3253.2025.02.001

Abstract

Abstract:

With the release of the 2025-NCCN （V1） Prostate Cancer Diagnosis and Treatment Guidelines，this article interprets the recent updates of the NCCN Prostate Cancer Diagnosis and Treatment Guidelines.The main content of the guidelines updates is the treatment recommendations for very low-risk prostate cancer，recurrence after radical radiotherapy or radical surgery，and metastatic castration resistant prostate cancer.Another focus is the prevention and treatment of bone related adverse events in prostate cancer.Interpreting the new version of the guidelines can provide clinicians with better strategies and treatment choices for the standardized diagnosis and treatment of prostate cancer，thereby further improving patient survival benefits.

Key words: Prostate cancer, Active surveillance, Recurrence, Gene testing, Molecular pathology, Bone health

Yonghong Li, Jun Wang, Hengjun Xiao. Interpretation updates of the 2025 NCCN Guidelines on diagnosis and treatment for prostate cancer[J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(02): 129-133.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2025.02.001

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2025/V19/I02/129

References 22

［1］	National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology： Prostate Cancer （version 1.2025）［EB/OL］.https：//www.nccn.org.
［2］	National Comprehensive Cancer Network.NCCN Guidelines for Genetic/Familial High-Risk Assessment： Breast，Ovarian，Pancreatic and Prostate （Version 2.2025）［EB/OL］.https：//www.nccn.org.
［3］	National Comprehensive Cancer Network.NCCN Guidelines for Genetic/Familial High-Risk Assessment： Colorectal，Endometrial，and Gastric （Version 2.2025）［EB/OL］.https：//www.nccn.org.
［4］	Chi KN，Barnicle A，Sibilla C，et al.Detection of BRCA1，BRCA2，and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound［J］.Clin Cancer Res，2023，29（1）：81-91.DOI： 10.1158/1078-0432.CCR-22-0931.
［5］	Tukachinsky H，Madison RW，Chung JH，et al.Genomic analysis of circulating tumor DNA in 3，334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms［J］.Clin Cancer Res，2021，27（11）： 3094-3105.DOI：10.1158/1078-0432.CCR-20-4805.
［6］	Vince RA Jr，Jiang R，Qi J，et al.Impact of decipher biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative［J］.Prostate Cancer Prostatic Dis，2022，25（4）：677-683.DOI： 10.1038/s41391-021-00428-y.
［7］	Spratt DE，Liu VYT，Michalski J，et al.Genomic classifier performance in intermediate-risk prostate cancer： results from NRG oncology/RTOG 0126 randomized phase 3 trial［J］.Int J Radiat Oncol Biol Phys，2023，117（2）： 370-377.DOI： 10.1016/j.ijrobp.2023.04.010.
［8］	Nguyen PL，Huang H，Spratt DE，et al.Analysis of a biopsy-based genomic classifier in high-risk prostate cancer： meta-analysis of the NRG oncology/radiation therapy oncology group 9202，9413，and 9902 phase 3 randomized trials［J］.Int J Radiat Oncol，2023，116（3）：521-529.DOI： 10.1016/j.ijrobp.2022.12.035.
［9］	Feng FY，Huang HC，Spratt DE，et al.Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer： an ancillary study of the NRG/RTOG 9601 randomized clinical trial［J］.JAMA Oncol，2021，7（4）： 544-552.DOI： 10.1001/jamaoncol.2020.7671.
［10］	Dal Pra A，Ghadjar P，Hayoz S，et al.Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial［J］.Ann Oncol，2022，33（9）： 950-958.DOI： 10.1016/j.annonc.2022.05.007.
［11］	Ross AE，Zhang J，Huang HC，et al.External validation of a digital pathology-based multimodal artificial intelligence architecture in the NRG/RTOG 9902 phase 3 trial［J］.Eur Urol Oncol，2024，7（5）： 1024-1033.DOI： 10.1016/j.euo.2024.01.004.
［12］	蔡欣旸，范宇，李永红.前列腺癌主动监测的研究进展［J］.中华泌尿外科杂志，2024，45（6）： 477-480.DOI： 10.3760/cma.j.cn112330-20240110-00019.Cai XY，Fan Y，Li YH.The progress of active surveillance of prostate cancer［J］.Chin J Urol，2024，45（6）： 477-480.DOI： 10.3760/cma.j.cn112330-20240110-00019.
［13］	Kyriakopoulos CE，Chen YH，Carducci MA，et al.Chemohormonal therapy in metastatic hormone-sensitive prostate cancer： long-term survival analysis of the randomized phase III E3805 CHAARTED trial［J］.J Clin Oncol，2018，36（11）： 1080-1087.DOI： 10.1200/JCO.2017.75.3657.
［14］	Abida W，Cheng ML，Armenia J，et al.Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade［J］.JAMA Oncol，2019，5（4）： 471-478.DOI：10.1001/jamaoncol.2018.5801.
［15］	Latham A，Srinivasan P，Kemel Y，et al.Microsatellite instability is associated with the presence of lynch syndrome pan-cancer［J］.J Clin Oncol，2019，37（4）： 286-295.DOI： 10.1200/JCO.18.00283.
［16］	Antonarakis ES，Piulats JM，Gross-Goupil M，et al.Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer： multicohort，open-label phase II KEYNOTE-199 study［J］.J Clin Oncol，2020，38（5）： 395-405.DOI： 10.1200/JCO.19.01638.
［17］	Fracture Risk Assessment Tool.University of Sheffield ［EB/OL］.http：//www.shef.ac.uk/FRAX/.
［18］	LeBoff MS，Greenspan SL，Insogna KL，et al.The clinician's guide to prevention and treatment of osteoporosis［J］.Osteoporos Int，2022，33（10）： 2049-2102.DOI： 10.1007/s00198-021-05900-y.
［19］	Himelstein AL，Foster JC，Khatcheressian JL，et al.Effect of longerinterval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases： a randomized clinical trial［J］.JAMA，2017，317（1）： 48-58.DOI： 10.1001/jama.2016.19425.
［20］	Clemons M，Ong M，Stober C，et al.A randomised trial of 4-versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer［J］.Eur J Cancer，2021，142： 132-140.DOI： 10.1016/j.ejca.2020.08.019.
［21］	南方护骨联盟前列腺癌骨转移专家组.前列腺癌骨转移诊疗专家共识（2023 版）［J/OL］.中华腔镜泌尿外科杂志（电子版），2023，17（3）： 201-208.DOI：10.3877/cma.j.issn.1674-3253.2023.03.001.Southern Alliance for Bone Care Prostate Cancer Bone Metastasis Expert Panel.Expert consensus on the diagnosis and treatment of prostate cancer bone metastasis （2023 edition）［J/OL］.Chin J Endourol （Electronic Edition），2023，17（3）： 201-208.DOI：10.3877/cma.j.issn.1674-3253.2023.03.001.
［22］	中国抗癌协会泌尿男生殖系统肿瘤专业委员会.前列腺癌骨转移和骨相关疾病临床诊疗专家共识（2021 版）［J］.中华肿瘤杂志，2021，43（10）： 1016-1026.DOI：10.3760/cma.j.cn112152-20210714-00513.Chinese Anti-Cancer Association Urogenital Tumor Committee.Expert consensus on clinical diagnosis and treatment of prostate cancer bone metastasis and bone-related diseases （2021 edition）［J］.Chin J Cancer，2021，43（10）： 1016-1026.DOI：10.3760/cma.j.cn112152-20210714-00513.

[1]	Yang Wei, Yuanquan Zhao, Xiaobo Wang, Hai Huang, Jie Chen. Risk analysis and prediction model establishment of early recurrence in patients with BCLC stage 0/A hepatocellular carcinoma after postoperative adjuvant therapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(02): 157-161.
[2]	Liuqing Li, Xiaoxiang Chen, Chengyu Lv. Comparison of total laparoscopic and laparoscopic assisted radical gastrectomy in the treatment of advanced gastric cancer in the near and medium term [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 23-26.
[3]	Shijun Liu, Jie Ma, Lujing Shi. Near-and medium-term follow-up study of complete mesangectomy plus standard D2 radical resection for advanced gastric cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 27-30.
[4]	Tianwei Xie, Yufan Pang, Li Wu. Effect of different ultrasound-guided ablation on the volume reduction rate and recurrence rate of benign thyroid nodules [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 80-83.
[5]	Fan Feng, Wenliang Ma, Xiang Dong, Jun Pan, Weidong Gan, Hongqian Guo. An evidence-based analysis in early postoperation： robot-assisted laparoscopic radical prostatectomy combined anterior and posterior approach [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(01): 83-87.
[6]	Tianlong Luo, Qingqing He, Hai Huang. Long-term comprehensive management of chronic urinary dysfunction and the practice of sustainable rehabilitation [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(01): 21-26.
[7]	Hongzhou Zhao, Guoxian Wei, Long Liu, Nianbin Yang, Dan Li. Comparison of the therapeutic effects and recurrence rates between laparoscopic hernia repair and traditional hernia repair in the treatment of inguinal hernia [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2025, 19(01): 79-82.
[8]	Lijian Wang, Manman Cheng, Bo Jiang, Youwen Zhang, Haixiang Wei, Xiao Han. Analysis of surgical outcomes and recurrence risk of refractory spontaneous pneumothorax in patients [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(01): 104-109.
[9]	Chengshu Yu, Hongzhi Liu, Kecan Lin, Qizhu Lin, Tingfeng Huang, Weiping Zhou, Zhangjun Cheng, Jianying Lou, Shuguo Zheng, Xinyu Bi, Jianming Wang, Wei Guo, Fuyu Li, Jian Wang, Yamin Zheng, Jingdong Li, Shi Cheng, Yongyi Zeng. Risk factors of very early recurrence of intrahepatic cholangiocarcinoma after surgery [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 53-59.
[10]	Jiqing Shi, Kun Li, Yifeng Chen. Rare giant bile duct cyst with new-onset liver neoplasm nine years after surgary: a cast report [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 126-127.
[11]	Zexin Yin, Jilin Yang, Youyao Li, Meilong Wu, Liping Liu. Research progress in preoperative prediction of microvascular invasion in liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 128-134.
[12]	Yu Gong, Yuan Liao, Mei Shang. Influencing factors and prediction model for recurrence of hepatocellular carcinoma after TACE [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 818-824.
[13]	Zhendong Jiao, Peng Hui, Shangbo Jin. Application of three-dimensional visualization combined with ICG imaging technology in laparoscopic hepatectomy for recurrent hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 859-864.
[14]	Hongliang Duan, Hongmei Zhao, Tao Li, Jianfeng Xin. Relationship between SPOCD1 expression and clinicopathological features, postoperative recurrence and metastasis in colorectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(01): 40-45.
[15]	Zhaorong Guo, Xinguang Wang, Yiqiang Liu, Yingjian He, Lize Wang, Yang Yang, Xing Wang, Wei Cao, Chongshan Gu, Tie Fan, Jinfeng Li, Zhaoqing Fan. Clinicopathologic characteristics and prognostic risk factors of different subtypes of phyllodes tumor of the breast [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(06): 524-532.

Please choose a citation manager

Content to export